You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePrednicarbate
Accession NumberDB01130  (APRD01197)
TypeSmall Molecule
GroupsApproved
DescriptionPrednicarbate is a relatively new topical corticosteroid drug. It is similar in potency to hydrocortisone. It is used in the treatment of inflammatory skin diseases, such as atopic dermatitis. It has a favorable benefit-risk ratio, with an inflammatory action similar to that of a medium potency corticosteroid, but with a low potential to cause skin atrophy. The anti-inflammation action of corticosteroids is associated with the inhibition of the interleukin 1-alpha cytokine within keratinocytes. IL-1a is also found in fibroblasts, where it is responsible for proliferation, collagenase induction and IL-6 synthesis, which are related to skin thickness.
Structure
Thumb
SynonymsNot Available
External Identifiers
  • LAS-189961
  • LAS189961
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DermatopCream1 mg/gTopicalValeant Pharmaceuticals North America LLC1993-10-29Not applicableUs
DermatopOintment1 mg/gTopicalValeant Pharmaceuticals North America LLC2014-06-23Not applicableUs
Dermatop Emollient CreamCream0.1 %TopicalValeant Canada Lp Valeant Canada S.E.C.2001-03-21Not applicableCanada
Dermatop OintmentOintment0.1 %TopicalValeant Canada Lp Valeant Canada S.E.C.2001-03-21Not applicableCanada
PrednicarbateCream1 mg/gTopicalPrasco Laboratories2007-04-30Not applicableUs
PrednicarbateCream1 mg/gTopicalOceanside Pharmaceuticals1993-10-29Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PrednicarbateCream1 mg/gTopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2006-09-19Not applicableUs
PrednicarbateOintment1 mg/gTopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2007-03-09Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Dermatop E EmollientNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIV901LV1K7D
CAS number73771-04-7
WeightAverage: 488.577
Monoisotopic: 488.241018119
Chemical FormulaC27H36O8
InChI KeyFNPXMHRZILFCKX-KAJVQRHHSA-N
InChI
InChI=1S/C27H36O8/c1-5-22(31)34-15-21(30)27(35-24(32)33-6-2)12-10-19-18-8-7-16-13-17(28)9-11-25(16,3)23(18)20(29)14-26(19,27)4/h9,11,13,18-20,23,29H,5-8,10,12,14-15H2,1-4H3/t18-,19-,20-,23+,25-,26-,27-/m0/s1
IUPAC Name
2-[(1S,2R,10S,11S,14R,15S,17S)-14-[(ethoxycarbonyl)oxy]-17-hydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-14-yl]-2-oxoethyl propanoate
SMILES
[H][C@@]12CC[C@](OC(=O)OCC)(C(=O)COC(=O)CC)[C@@]1(C)C[[email protected]](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Pharmacology
IndicationFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Structured Indications
PharmacodynamicsCorticosteroids diffuse across cell membranes and complex with specific cytoplasmic receptors. These complexes then enter the cell nucleus, bind to DNA (chromatin), and stimulate transcription of messenger RNA (mRNA) and subsequent protein synthesis of various inhibitory enzymes responsible for the anti-inflammatory effects of topical corticosteroids. These anti-inflammatory effects include inhibition of early processes such as edema, fibrin deposition, capillary dilatation, movement of phagocytes into the area, and phagocytic activities. Later processes, such as capillary production, collagen deposition, and keloid formation also are inhibited by corticosteroids.
Mechanism of actionIn common with other topical corticosteroids, prednicarbate has anti-inflammatory, antipruritic, and vasoconstrictive properties. In general, the mechanism of the anti-inflammatory activity of topical steroids is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
TargetKindPharmacological actionActionsOrganismUniProt ID
Glucocorticoid receptorProteinyes
agonist
HumanP04150 details
Related Articles
AbsorptionAbsorbed systemically across the stratum corneum.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Primarily in skin

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Prednicarbate is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Prednicarbate.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Prednicarbate.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Prednicarbate.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Prednicarbate.Approved
AldesleukinPrednicarbate may decrease the antineoplastic activities of Aldesleukin.Approved
ALT-110The risk or severity of adverse effects can be increased when Prednicarbate is combined with ALT-110.Investigational
Aluminum hydroxideThe bioavailability of Prednicarbate can be decreased when combined with Aluminum hydroxide.Approved
Aluminum phosphateThe bioavailability of Prednicarbate can be decreased when combined with Aluminum phosphate.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Prednicarbate.Approved
AmiodaroneThe serum concentration of Prednicarbate can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BPrednicarbate may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Prednicarbate.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Prednicarbate.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Prednicarbate.Approved, Investigational
AprepitantThe serum concentration of Prednicarbate can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Prednicarbate can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Prednicarbate.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Prednicarbate.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Prednicarbate.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Prednicarbate.Approved, Investigational
BazedoxifeneThe serum concentration of Prednicarbate can be increased when it is combined with Bazedoxifene.Approved, Investigational
BendroflumethiazidePrednicarbate may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Prednicarbate.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Prednicarbate.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Prednicarbate.Investigational
Bismuth SubcitrateThe bioavailability of Prednicarbate can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe serum concentration of Prednicarbate can be increased when it is combined with Boceprevir.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Prednicarbate.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Prednicarbate.Investigational
BumetanidePrednicarbate may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Prednicarbate.Approved, Nutraceutical
Calcium carbonateThe bioavailability of Prednicarbate can be decreased when combined with Calcium carbonate.Approved
CarbamazepineThe serum concentration of Prednicarbate can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Prednicarbate.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Prednicarbate.Experimental
CDX-110The risk or severity of adverse effects can be increased when Prednicarbate is combined with CDX-110.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Prednicarbate.Approved, Investigational
CeritinibPrednicarbate may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Prednicarbate.Approved, Vet Approved
ChlorothiazidePrednicarbate may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Prednicarbate can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorthalidonePrednicarbate may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Prednicarbate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe serum concentration of Prednicarbate can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Prednicarbate.Approved
CobicistatThe serum concentration of Prednicarbate can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Prednicarbate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Prednicarbate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated Equine EstrogensThe serum concentration of Prednicarbate can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Prednicarbate.Approved
CoumaphosThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Prednicarbate.Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Prednicarbate.Investigational
DarunavirThe serum concentration of Prednicarbate can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Prednicarbate.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Prednicarbate.Approved, Vet Approved
DienestrolThe serum concentration of Prednicarbate can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Prednicarbate can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Prednicarbate.Approved
DihydrotestosteronePrednicarbate may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DonepezilThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Prednicarbate.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Prednicarbate.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Prednicarbate.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Prednicarbate.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Prednicarbate can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Prednicarbate.Approved
EstradiolThe serum concentration of Prednicarbate can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Prednicarbate can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Prednicarbate can be increased when it is combined with Estrone.Approved
Etacrynic acidPrednicarbate may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Prednicarbate.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Prednicarbate can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Prednicarbate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Prednicarbate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Prednicarbate.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Prednicarbate.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Prednicarbate.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Prednicarbate.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Prednicarbate.Approved
FenthionThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Fenthion.Vet Approved
FleroxacinThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Prednicarbate.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Prednicarbate.Vet Approved
FluoxymesteronePrednicarbate may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Prednicarbate.Approved, Investigational
FosaprepitantThe serum concentration of Prednicarbate can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Prednicarbate can be decreased when it is combined with Fosphenytoin.Approved
FurosemidePrednicarbate may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Prednicarbate is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Prednicarbate can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Prednicarbate is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Ginkgo biloba.Approved, Nutraceutical
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Prednicarbate.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Grepafloxacin.Withdrawn
HexestrolThe serum concentration of Prednicarbate can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Prednicarbate.Investigational
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Prednicarbate.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prednicarbate.Approved, Investigational
HydrochlorothiazidePrednicarbate may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazidePrednicarbate may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Prednicarbate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Prednicarbate.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Prednicarbate.Approved
IdelalisibThe serum concentration of Prednicarbate can be increased when it is combined with Idelalisib.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Prednicarbate.Approved
IndapamidePrednicarbate may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Prednicarbate can be increased when it is combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Prednicarbate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Prednicarbate.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Prednicarbate is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Prednicarbate is combined with INGN 225.Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Prednicarbate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Prednicarbate.Withdrawn
ItraconazoleThe serum concentration of Prednicarbate can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Prednicarbate.Experimental
KetoconazoleThe serum concentration of Prednicarbate can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Prednicarbate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Prednicarbate.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Prednicarbate.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Prednicarbate.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Lomefloxacin.Approved
LopinavirThe serum concentration of Prednicarbate can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Prednicarbate.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Prednicarbate.Approved
LumacaftorThe serum concentration of Prednicarbate can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Prednicarbate.Approved, Investigational
MagaldrateThe bioavailability of Prednicarbate can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Prednicarbate can be decreased when combined with Magnesium carbonate.Approved
Magnesium hydroxideThe bioavailability of Prednicarbate can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Prednicarbate can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Prednicarbate.Approved
Magnesium TrisilicateThe bioavailability of Prednicarbate can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Prednicarbate.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prednicarbate.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Prednicarbate.Approved
MefloquineThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Prednicarbate.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Prednicarbate.Approved
MestranolThe serum concentration of Prednicarbate can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Prednicarbate.Withdrawn
MethallenestrilThe serum concentration of Prednicarbate can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazidePrednicarbate may increase the hypokalemic activities of Methyclothiazide.Approved
MethyltestosteronePrednicarbate may increase the fluid retaining activities of Methyltestosterone.Approved
MetolazonePrednicarbate may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Prednicarbate can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Minaprine.Approved
MitotaneThe serum concentration of Prednicarbate can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Prednicarbate.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Prednicarbate.Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Prednicarbate.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prednicarbate.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Prednicarbate.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Prednicarbate.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Prednicarbate.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Prednicarbate.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Prednicarbate.Investigational
NefazodoneThe serum concentration of Prednicarbate can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Prednicarbate can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Prednicarbate.Approved
NevirapineThe serum concentration of Prednicarbate can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Nicorandil.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Prednicarbate.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Prednicarbate.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Prednicarbate.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Ofloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Prednicarbate.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Prednicarbate.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Prednicarbate.Vet Approved
OxandrolonePrednicarbate may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Prednicarbate.Approved
OxymetholonePrednicarbate may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Prednicarbate.Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Prednicarbate.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Prednicarbate can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Prednicarbate can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Prednicarbate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Prednicarbate.Approved, Vet Approved
PhenytoinThe serum concentration of Prednicarbate can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Prednicarbate.Approved, Investigational
PiretanidePrednicarbate may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Prednicarbate.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Prednicarbate.Approved, Investigational
Polyestradiol phosphateThe serum concentration of Prednicarbate can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazidePrednicarbate may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Prednicarbate can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe serum concentration of Prednicarbate can be decreased when it is combined with Primidone.Approved, Vet Approved
PromestrieneThe serum concentration of Prednicarbate can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Prednicarbate.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Prednicarbate.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Prednicarbate can be increased when it is combined with Quinestrol.Approved
QuinethazonePrednicarbate may increase the hypokalemic activities of Quinethazone.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Rabies vaccine.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Prednicarbate.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Prednicarbate.Experimental, Investigational
RifabutinThe serum concentration of Prednicarbate can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Prednicarbate can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Prednicarbate can be decreased when it is combined with Rifapentine.Approved
RitonavirThe serum concentration of Prednicarbate can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Prednicarbate.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Rosoxacin.Approved
S EquolThe serum concentration of Prednicarbate can be increased when it is combined with S Equol.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Prednicarbate.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Prednicarbate.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Prednicarbate.Approved
SaquinavirThe serum concentration of Prednicarbate can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Prednicarbate can be increased when it is combined with Secoisolariciresinol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Prednicarbate.Approved, Investigational
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Prednicarbate.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when Prednicarbate is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Prednicarbate.Investigational
St. John's WortThe serum concentration of Prednicarbate can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololPrednicarbate may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Prednicarbate.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Prednicarbate.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Prednicarbate.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Prednicarbate can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Prednicarbate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Tacrine.Withdrawn
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Prednicarbate.Approved
TelithromycinThe serum concentration of Prednicarbate can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Temafloxacin.Withdrawn
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Prednicarbate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Prednicarbate.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Prednicarbate.Approved
TestosteronePrednicarbate may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Prednicarbate is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Prednicarbate.Approved
TiboloneThe serum concentration of Prednicarbate can be increased when it is combined with Tibolone.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Prednicarbate.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Prednicarbate.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Prednicarbate.Approved
TorasemidePrednicarbate may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Prednicarbate.Approved, Investigational
TrichlorfonThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Trichlorfon.Vet Approved
TrichlormethiazidePrednicarbate may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Prednicarbate.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Prednicarbate.Investigational, Withdrawn
VoriconazoleThe serum concentration of Prednicarbate can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinPrednicarbate may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Prednicarbate.Approved
ZeranolThe serum concentration of Prednicarbate can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Prednicarbate.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Prednicarbate.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Gupta AK, Chow M: A review of prednicarbate (Dermatop). Skin Therapy Lett. 2004 Dec-2005 Jan;9(10):5-6, 9. [PubMed:15657633 ]
External Links
ATC CodesD07AC18
AHFS Codes
  • 84:06.00
  • 92:04.00*
PDB EntriesNot Available
FDA labelDownload (130 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9958
Blood Brain Barrier+0.984
Caco-2 permeable-0.571
P-glycoprotein substrateSubstrate0.7928
P-glycoprotein inhibitor IInhibitor0.8358
P-glycoprotein inhibitor IINon-inhibitor0.6129
Renal organic cation transporterNon-inhibitor0.7659
CYP450 2C9 substrateNon-substrate0.8753
CYP450 2D6 substrateNon-substrate0.895
CYP450 3A4 substrateSubstrate0.7638
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9054
CYP450 2D6 inhibitorNon-inhibitor0.9032
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.841
Ames testNon AMES toxic0.9186
CarcinogenicityNon-carcinogens0.9164
BiodegradationNot ready biodegradable0.9757
Rat acute toxicity2.4426 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8758
hERG inhibition (predictor II)Non-inhibitor0.5989
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
CreamTopical0.1 %
OintmentTopical0.1 %
CreamTopical1 mg/g
OintmentTopical1 mg/g
Prices
Unit descriptionCostUnit
Prednicarbate 0.1% Ointment 60 gm Tube76.74USD tube
Dermatop 0.1% Cream 60 gm Tube75.2USD tube
Dermatop 0.1% Ointment 60 gm Tube70.06USD tube
Prednicarbate 0.1% Cream 60 gm Tube59.03USD tube
Prednicarbate 0.1% Ointment 15 gm Tube37.31USD tube
Prednicarbate 0.1% Cream 15 gm Tube24.0USD tube
Dermatop 0.1% cream1.76USD g
Prednicarbate 0.1% cream1.41USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00562 mg/mLALOGPS
logP3.08ALOGPS
logP3.83ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)14.83ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area116.2 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity127.8 m3·mol-1ChemAxon
Polarizability52.43 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassPregnane steroids
Direct ParentGluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
Substituents
  • Progestogin-skeleton
  • Steroid ester
  • 20-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • 3-oxosteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Hydroxysteroid
  • Delta-1,4-steroid
  • Alpha-acyloxy ketone
  • Carbonic acid diester
  • Cyclic alcohol
  • Carbonic acid derivative
  • Ketone
  • Carboxylic acid ester
  • Secondary alcohol
  • Cyclic ketone
  • Carboxylic acid derivative
  • Monocarboxylic acid or derivatives
  • Organic oxygen compound
  • Carbonyl group
  • Hydrocarbon derivative
  • Alcohol
  • Organooxygen compound
  • Organic oxide
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Boudinot FD, D'Ambrosio R, Jusko WJ: Receptor-mediated pharmacodynamics of prednisolone in the rat. J Pharmacokinet Biopharm. 1986 Oct;14(5):469-93. [PubMed:2879901 ]
  2. Ikonomidis I, Tzortzis S, Lekakis J, Paraskevaidis I, Andreadou I, Nikolaou M, Kaplanoglou T, Katsimbri P, Skarantavos G, Soucacos P, Kremastinos DT: Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. Heart. 2009 Sep;95(18):1502-7. doi: 10.1136/hrt.2009.168971. Epub 2009 May 28. [PubMed:19482847 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23